1268520-70-2

Usage

Uses

Used in Organic Synthesis:
(3R,4R)-1-[(tert-butoxy)carbonyl]-4-ethylpyrrolidine-3-carboxyli is used as a protecting group in organic synthesis for the amino group of proline. The application reason is to prevent unwanted reactions during the synthesis process, ensuring the selective and efficient assembly of peptides.
Used in Peptide Chemistry:
In peptide chemistry, (3R,4R)-1-[(tert-butoxy)carbonyl]-4-ethylpyrrolidine-3-carboxyli is used as a protecting agent for the amino group of proline during peptide synthesis. The application reason is to facilitate the controlled formation of peptide bonds and to avoid side reactions that could compromise the integrity and yield of the desired peptide product.
Used in Pharmaceutical Industry:
(3R,4R)-1-[(tert-butoxy)carbonyl]-4-ethylpyrrolidine-3-carboxyli is used as a key intermediate in the development of pharmaceutical compounds, particularly in the synthesis of peptide-based drugs. The application reason is to enable the protection of the amino group during the drug synthesis process, which can later be removed to reveal the active pharmaceutical ingredient with the free amine group.
Used in Research and Development:
In the research and development sector, (3R,4R)-1-[(tert-butoxy)carbonyl]-4-ethylpyrrolidine-3-carboxyli is used as a valuable tool for studying the properties and reactivity of proline-containing peptides. The application reason is to gain insights into the structure-activity relationships of these peptides, which can lead to the discovery of new therapeutic agents and a better understanding of their biological functions.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 55314-57-3 ethyl pent-2-ynoate 
• 51814-19-8 1-Benzyloxycarbonyl-4-ethoxycarbonyl-3-oxopyrrolidine 

Downstream Products

• 1310726-60-3 (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide 
• 1428243-26-8 (3R,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate 
• 1428243-27-9 (3R,4S)-benzyl 3-(2-(tert-butoxycarbonyl(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)amino)acetyl)-4-ethylpyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

Synthesis method of JAK inhibitor intermediates

The invention discloses a synthesis method of JAK inhibitor intermediates. The method comprises the steps that a compound (2) serves as the raw material and reacts with ethylboric acid in the presenceof a catalyst, sodium phosphate and a phase transfer ca

Method for synthesizing upadacitinib intermediate and the intermediate

The invention discloses a method for synthesizing upadacitinib intermediate. The method includes performing a ring-forming reaction with 2-pentynoate and N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine under a catalyst A to prepare a compound (3), by which the compound (7) or the compound (8) can be obtained in various manners. The method especially the first and the third technical schemes,is high in yield and purity and is high in overall yield. The method is simple in post-treatment and is suitable for industrial large-scale production.

Upadacitinib tartrate: Tyrosine-protein kinase JAK1 inhibitor Treatment of autoimmune inflammatory diseases Treatment of rheumatoid arthritis

Upadacitinib tartrate (ABT-494) is a potent and selective tyrosine-protein kinase JAK1 inhibitor being developed for the treatment of systemic autoimmune inflammatory diseases, including rheumatoid arthritis (RA), Crohn's disease, ulcerative colitis and psoriatic arthritis. In vitro, upadacitinib demonstrated higher selectivity for inhibiting JAK1 over JAK2 and JAK3, suggesting a potentially improved therapeutic profile in treating patients with inflammatory diseases compared to nonselective JAK inhibitors. Upadacitinib has demonstrated safety and efficacy in phase II trials in patients with RA and inflammatory bowel disease, and is currently in phase III development for these indications.

NOVEL COMPOUNDS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.